Flosonics Medical Secures $7.5 Million CAD Venture Debt to Scale Wearable Ultrasound Technology

Flosonics Medical, a Canadian medical device innovator, has secured $7.5 million CAD in venture debt financing from RBCx to accelerate the growth and market adoption of FloPatch, the world’s first wireless wearable ultrasound device. Designed to transform fluid management in critical care, FloPatch empowers clinicians to make faster, more informed decisions at the bedside, improving patient outcomes and operational efficiencies.

FloPatch is a wireless, wearable Doppler ultrasound device that enables rapid, repeatable hemodynamic assessments to determine a patient’s fluid responsiveness. This capability allows clinicians to deliver timely and effective interventions, particularly in fast-paced environments like emergency departments and intensive care units. By streamlining critical decisions, FloPatch helps healthcare providers optimize sepsis care, reduce fluid-related complications, and enhance patient outcomes.

Sepsis, a leading cause of in-hospital deaths, affects over 75,000 patients annually in Canada and 1.7 million in the U.S. Traditional Doppler ultrasound machines, while effective, are often cumbersome and time-intensive, limiting their accessibility in critical care settings. FloPatch addresses this gap by offering a portable, non-invasive solution that integrates seamlessly into clinical workflows.

RBCx, the tech and innovation banking arm of RBC, is the first Canadian bank to offer a dedicated life sciences credit advisory team. Led by Anne Woods, Managing Director of RBCx’s national Life Sciences practice, the team provides tailored financing and strategic expertise to support venture-backed life sciences companies.

“Flosonics Medical is a great example of the transformative potential of Canada’s life sciences sector, and we’re longtime supporters of their mission,” said Woods. “We’re proud to back the scaling ambitions of companies like Flosonics Medical with the capital they need to improve patient care through bold innovations like FloPatch.”

“We’re thrilled to be working with RBCx as we bring FloPatch to more hospitals across North America and beyond,” said Joe Eibl, CEO and co-founder of Flosonics Medical. “This financing allows us to accelerate our mission of equipping healthcare providers with the tools they need to deliver the highest quality of care possible while improving operational efficiencies in hospitals.”

With this funding, Flosonics Medical is poised to expand the reach of FloPatch, solidifying its position as a leader in life sciences innovation and advancing its mission to revolutionize critical care through wearable ultrasound technology.